May 13 (Reuters) – Mylan NV said it would buy a part
of the topicals-focused drug business of Renaissance Acquisition
Holdings LLC for $950 million to expand its dermatological
product portfolio.
The post UPDATE 1-Mylan to buy Renaissance’s topical business for $950 mln appeared first on NASDAQ.